BetterLife Pharma (BETRF) Common Equity (2011 - 2026)
BetterLife Pharma (BETRF) posted quarterly Common Equity of -$4.7 million for Q2 2026, down 9.79% year-over-year from -$5.2 million in Q2 2025, and little changed quarter-over-quarter from -$4.7 million in Q1 2026.
BetterLife Pharma (BETRF) Common Equity (2011 - 2026) Analysis & Trends
BetterLife Pharma's Common Equity history runs 16 years deep, the most recent figure standing at -$4.7 million for Q2 2026.
- In Q2 2026, Common Equity fell 9.79% year-over-year to -$4.7 million; the TTM figure through Apr 2026 stood at -$4.7 million (down 9.79% YoY), while the FY2026 annual figure was -$4.7 million, up 9.88% from the prior year.
- Common Equity for Q2 2026 stood at -$4.7 million, roughly flat from -$4.7 million in the prior quarter.
- The five-year high for Common Equity was -$3.1 million in Q1 2022, with the low at -$5.7 million in Q2 2024.
- The 5-year median for Common Equity is -$4.9 million (2023), against an average of -$4.9 million.
- The sharpest annual moves came in 2022 and 2025: Common Equity sank 726.29% in 2022, then climbed 25.44% in 2025.
- BetterLife Pharma's Common Equity stood at -$5.0 million in 2022, then grew by 1.19% to -$4.9 million in 2023, then gained by 1.18% to -$4.9 million in 2024, then increased by 13.09% to -$4.2 million in 2025, then declined by 10.99% to -$4.7 million in 2026.
- Business Quant data shows BETRF's Common Equity at -$4.7 million in Q2 2026, -$4.7 million in Q1 2026, and -$4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | BetterLife Pharma | 36.45 Mn | 36.42 Mn | - | -4.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -4.69 Mn |
| Jan 31, 2026 | -4.67 Mn |
| Jul 31, 2025 | -4.23 Mn |
| Apr 30, 2025 | -4.28 Mn |
| Jan 31, 2025 | -5.19 Mn |
| Oct 31, 2024 | -4.87 Mn |
| Jul 31, 2024 | -5.53 Mn |
| Apr 30, 2024 | -5.73 Mn |
| Jan 31, 2024 | -5.69 Mn |
| Oct 31, 2023 | -4.92 Mn |
| Jul 31, 2023 | -5.23 Mn |
| Apr 30, 2023 | -4.73 Mn |
| Jan 31, 2023 | -5.59 Mn |
| Oct 31, 2022 | -4.98 Mn |
| Jul 31, 2022 | -5.27 Mn |
| Apr 30, 2022 | -4.90 Mn |
| Jan 31, 2022 | -3.07 Mn |
| Oct 31, 2021 | -603,179.67 |
| Jul 31, 2021 | 1.03 Mn |
| Apr 30, 2021 | -3.04 Mn |